Charles J. Homcy, Director at BridgeBio Pharma, Inc. (BBIO), sold 550,000 shares at $46.64 ($25.4M) on 2025-08-08, disclosed to the SEC on 2025-08-12.
Scheduled sale ($25.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.87 | 191,662 | $8.8M | 34.6% |
| 2 | $45.87 | 191,662 | $8.8M | 34.6% |
| 3 | $46.64 | 58,338 | $2.7M | 10.7% |
| 4 | $46.64 | 58,338 | $2.7M | 10.7% |
| 5 | $48.00 | 50,000 | $2.4M | 9.4% |
| Total | $46.23 avg | 550,000 |
| $25.4M |
| 100% |
| Filing → |
| BBIO | SELL | 2020-09-29 | $6.7M | — | Filing → |
| BBIO | SELL | 2020-02-12 | $720K | — | Filing → |
| BBIO | SELL | 2020-01-16 | $350K | — | Filing → |